You have read all your free articles, to continue reading subscribe to read the rest of this content.
Lundbeck has expanded its clinical-stage pipeline and initiates the AMULET study, which is designed to confirm the potential of Lu AF82422 as a treatment to slow the rate of disease progression of multiple system atrophy (MSA). Earlier this year, Lu AF82422 was granted orphan drug designation by Already a subscriber…
Evaxion Biotech has announced preclinical data demonstrating the effectiveness of its AI-driven viral vaccine discovery platform. The presented preclinical study was conducted in collaboration with associate professor Girish Kirimanjeswara, Pennsylvania State University, US. Our RAVEN platform rAlready a subscriber Login You have read all your free articles, to continue reading…
Affibody has announced the completion of the ABY-039 Phase 1 trial, and the termination of the ABY-039 program due to tolerability observations that would limit the target product profile of subcutaneous high dose once monthly maintentance injections. Based on these observations Alexion has termiAlready a subscriber Login You have read…
Danish biotech company Orphazyme raised a €20 million ($24 million US) B round to pay for its work on rare lysosomal storage disorders as it moves toward Phase II trials. Investors included Novo Nordisk's venture arm. Orphazyme's lead candidate, Orph002, is a treatment for Niemann-Pick diseasAlready a subscriber Login You…
